Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Nivaquine

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Klorokin Testmiljö

Klorokin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. UK Teratology Information Service (UKTIS). Use of chloroquine in pregnancy Aug 2023 Ver 4. UKTIS [www]. [cited 2024-05-12].

  2. Andersson NW, Skov L, Andersen JT. Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology (Oxford). 2021;60(5):2317-2326.

  3. McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12:388-96.

  4. Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere R, Schildknecht J, Fuchs E et al. Safety of mefloquine and other antimalarial agents in first trimester of pregnancy. J Travel Med 1998;5:121-6.

  5. Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg. 1996;55:50-6.

  6. Wolfe MS, Cordero JF. Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J (Clin Res Ed). 1985;290:1466-7.

  7. Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst Rev. 2014;10:CD000169.

  8. Orton LC, Omari AA. Drugs for treating uncomplicated malaria in pregnant women. Cochrane Database Syst Rev. 2008;4:CD004912.

  9. Patatt FSA, Sampaio ALL, Tauil PL, Oliveira CACP. Hearing of neonates without risk indicators for hearing loss and use of antimalarial drugs during pregnancy: a historical cohort study in the Northern Region of Brazil. Braz J Otorhinolaryngol. 2019 Jul 23. pii: S1808-8694(18)30466-X. doi: 10.1016/j.bjorl.2019.06.005

  10. Borba EF, Turrini-Filho JR, Kuruma KA, Bertola C, Pedalini ME, Lorenzi MC et al. Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. Lupus. 2004;13:223-7.

  11. Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol. 1991;8:174-8.

  12. Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol. 2011;38:2504-8.

  1. UK Teratology Information Service (UKTIS). Use of chloroquine in pregnancy Aug 2023 Ver 4. UKTIS [www]. [cited 2024-05-12].
  2. Andersson NW, Skov L, Andersen JT. Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology (Oxford). 2021;60(5):2317-2326.
  3. McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12:388-96.
  4. Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere R, Schildknecht J, Fuchs E et al. Safety of mefloquine and other antimalarial agents in first trimester of pregnancy. J Travel Med 1998;5:121-6.
  5. Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL, Breman JG. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg. 1996;55:50-6.
  6. Wolfe MS, Cordero JF. Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J (Clin Res Ed). 1985;290:1466-7.
  7. Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst Rev. 2014;10:CD000169.
  8. Orton LC, Omari AA. Drugs for treating uncomplicated malaria in pregnant women. Cochrane Database Syst Rev. 2008;4:CD004912.
  9. Patatt FSA, Sampaio ALL, Tauil PL, Oliveira CACP. Hearing of neonates without risk indicators for hearing loss and use of antimalarial drugs during pregnancy: a historical cohort study in the Northern Region of Brazil. Braz J Otorhinolaryngol. 2019 Jul 23. pii: S1808-8694(18)30466-X. doi: 10.1016/j.bjorl.2019.06.005
  10. Borba EF, Turrini-Filho JR, Kuruma KA, Bertola C, Pedalini ME, Lorenzi MC et al. Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. Lupus. 2004;13:223-7.
  11. Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol. 1991;8:174-8.
  12. Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol. 2011;38:2504-8.